Clinical Trials
9 trialsNCT06137144 2026-05-19
PRIMAVERA
AstraZeneca
Phase 1/2 Recruiting
NCT03598608 2026-02-05
MK-4280-003
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT02783300 2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1 Completed
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03454451 2023-12-21
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT01953692 2021-08-04
MK-3475-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02501473 2020-09-09
MK-3475-174
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Terminated